August 18, 2008 – Maximus, a business unit of infusion therapy firm Medegen Inc., today announced as a result of a co-marketing agreement between C.R. Bard and Medegen, the MaxPlus ClearT needleless access connector will now be included in peripherally inserted central catheter (PICC) kits sold by Bard Access Systems.
The agreement provides the benefits of the MaxPlus Clear product to users of Bard PowerPICC SOLO, the newly launched PICC designed to provide the efficiency of power injection for contrast enhanced CT scans and PICC therapy combined with the simplicity of saline care and maintenance through its innovative valve technology.
The MaxPlus Clear Needleless Access Device is one of the first positive displacement connectors to feature complete visualization of the fluid path, leading to lower bloodstream infection and occlusion rates, the company said.
The MaxPlus Clear Needleless Access Device will be packaged with all Bard PICC catheters and is also available directly from Maximus as a sterile, pouched product.
The companies said the inclusion of MaxPlus Clear in Bard PICC kits offers customers the benefit of a needleless access device designed to assist in the reduction of common catheter complications such as bloodstream infection and catheter occlusion. These complications typically result from blood reflux in the catheter, poor flushing, and inadequate disinfection of the access port.
MaxPlus Clear features Medegen's patented positive displacement technology, which provides a bolus of fluid to clear the catheter tip upon disconnection from the device. It also features Medegen’s patented Tru-Swab top which acts as a double sealed barrier to contamination and allows for true disinfection during pre-access swabbing and a clear housing minimizing the occurrence of poor flushing.
For more visit: www.medegen.com, www.bardaccess.com
August 21, 2026 
